Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
| (NASDAQ: ALLO) | Delayed: 1.43 -0.03 (2.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.46 | 52 Week High | $ | |||
| Open | $1.46 | 52 Week Low | $ | |||
| Day High | $1.47 | P/E | N/A | |||
| Day Low | $1.42 | EPS | $ | |||
| Volume | 3,896,630 | |||||
